Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model.
暂无分享,去创建一个
Olivier Elemento | O. Elemento | A. Melnick | Yanwen Jiang | L. Cerchietti | Ari Melnick | Yanwen Jiang | Leandro Cerchietti | Wei Du | Rebecca Goldstein | Omar Aly | W. Du | R. Goldstein | Omar Aly
[1] A. Tarakhovsky,et al. PKCβ modulates antigen receptor signaling via regulation of Btk membrane localization , 2001, The EMBO journal.
[2] Tilman Brummer,et al. Feedback regulation of lymphocyte signalling , 2004, Nature Reviews Immunology.
[3] J. Kutok,et al. Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma , 2012, Clinical Cancer Research.
[4] R. Lahesmaa,et al. Capturing cell-fate decisions from the molecular signatures of a receptor-dependent signaling response , 2007, Molecular systems biology.
[5] C. M. Cabrera,et al. Identity tests: determination of cell line cross-contamination , 2006, Cytotechnology.
[6] D. Krappmann,et al. CARD-Bcl10-Malt1 Signalosomes: Missing Link to NF-κB , 2007, Science's STKE.
[7] J. Andersen,et al. Enzyme kinetic characterization of protein tyrosine phosphatases. , 2003, Biochimie.
[8] M. Reth,et al. Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop. , 2002, Molecular cell.
[9] L. Staudt,et al. Diffuse large B-cell lymphoma—treatment approaches in the molecular era , 2014, Nature Reviews Clinical Oncology.
[10] John G Doench,et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. , 2013, Cancer cell.
[11] T. Kurosaki,et al. Protein kinase C mu (PKC mu) associates with the B cell antigen receptor complex and regulates lymphocyte signaling. , 1996, Immunity.
[12] S. Rhee,et al. Mechanism of B-Cell Receptor-Induced Phosphorylation and Activation of Phospholipase C-γ2 , 2004, Molecular and Cellular Biology.
[13] Sam Michael,et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells , 2014, Proceedings of the National Academy of Sciences.
[14] O. Elemento,et al. Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies , 2014, Oncogene.
[15] M. Reth,et al. Syk is a dual-specificity kinase that self-regulates the signal output from the B-cell antigen receptor , 2010, Proceedings of the National Academy of Sciences.
[16] H. Sanjo,et al. The Journal of Experimental Medicine CORRESPONDENCE , 2005 .
[17] Dominik Wodarz,et al. Tumor growth dynamics: insights into evolutionary processes. , 2013, Trends in ecology & evolution.
[18] A. Weiss,et al. Protein Kinase Cδ Promotes Transitional B Cell-Negative Selection and Limits Proximal B Cell Receptor Signaling To Enforce Tolerance , 2014, Molecular and Cellular Biology.
[19] Jan Delabie,et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.
[20] Lewis Luján Lm,et al. Cell growth curves for different cell lines and their relationship with biological activities , 2013 .
[21] Ali Mohammed,et al. Effects of harvesting stage and storage duration on postharvest quality and shelf life of sweet bell pepper (Capsicum annuum L.) varieties under passive refrigeration system , 2013 .
[22] Idan Tamir,et al. Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy. , 2011, Immunity.
[23] M. Baccarini,et al. MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the Maintenance of Peripheral Tolerance , 2013, Molecular cell.
[24] G. Mills,et al. Physical Association of PDK1 with AKT1 Is Sufficient for Pathway Activation Independent of Membrane Localization and Phosphatidylinositol 3 Kinase , 2010, PloS one.
[25] Tara L. Naylor,et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. , 2011, Cancer research.
[26] G. Lenz,et al. Critical role of PI3K signaling for NF-κB–dependent survival in a subset of activated B-cell–like diffuse large B-cell lymphoma cells , 2010, Proceedings of the National Academy of Sciences.
[27] H. Niiro,et al. Decision making in the immune system: Regulation of B-cell fate by antigen-receptor signals , 2002, Nature Reviews Immunology.
[28] R. Advani,et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Mariano J. Alvarez,et al. Quantitative modeling of the terminal differentiation of B cells and mechanisms of lymphomagenesis , 2012, Proceedings of the National Academy of Sciences.
[30] J. D. Dal Porto,et al. B cell antigen receptor signaling 101. , 2004, Molecular immunology.
[31] T. Kurosaki,et al. BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. , 2000, Immunity.
[32] Daniel C Kirouac,et al. Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors , 2013, Science Signaling.
[33] Doron Lancet,et al. MOPED: Model Organism Protein Expression Database , 2011, Nucleic Acids Res..
[34] R. Gascoyne,et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. , 2012, Cancer cell.
[35] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.
[36] J. Kinet,et al. BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity. , 2003, Immunity.
[37] Sanjay Jain,et al. Bistability in a model of early B cell receptor activation and its role in tonic signaling and system tunability. , 2013, Molecular bioSystems.
[38] William W. Chen,et al. Classic and contemporary approaches to modeling biochemical reactions. , 2010, Genes & development.
[39] M. Fujimoto,et al. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. , 2000, Immunity.
[40] S. Gauld,et al. Src-family kinases in B-cell development and signaling , 2004, Oncogene.
[41] L. Staudt,et al. Targeting pathological B cell receptor signalling in lymphoid malignancies , 2013, Nature Reviews Drug Discovery.
[42] Dipak Barua,et al. A Computational Model for Early Events in B Cell Antigen Receptor Signaling: Analysis of the Roles of Lyn and Fyn , 2012, The Journal of Immunology.
[43] G. Lenz,et al. Malt1-dependent RelB cleavage promotes canonical NF-κB activation in lymphocytes and lymphoma cell lines , 2011, Proceedings of the National Academy of Sciences.
[44] P. Marynen,et al. T cell antigen receptor stimulation induces MALT1 paracaspase–mediated cleavage of the NF-κB inhibitor A20 , 2008, Nature Immunology.
[45] James C. Stone,et al. RasGRP1 and RasGRP3 Regulate B Cell Proliferation by Facilitating B Cell Receptor-Ras Signaling1 , 2005, The Journal of Immunology.
[46] N. Varin‐Blank,et al. Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma , 2013, Experimental Hematology & Oncology.
[47] G. Packham,et al. B-cell receptor signaling in chronic lymphocytic leukemia. , 2011, Blood.
[48] Laurens P. Kil,et al. Targeting Bruton's tyrosine kinase in B cell malignancies , 2014, Nature Reviews Cancer.
[49] D. Krappmann,et al. CARD-Bcl10-Malt1 signalosomes: missing link to NF-kappaB. , 2007, Science's STKE : signal transduction knowledge environment.
[50] K. Moelling,et al. Phosphorylation and regulation of Raf by Akt (protein kinase B). , 1999, Science.
[51] D. Cantrell,et al. Protein kinase C and beyond , 2004, Nature Immunology.